Somatropin - JCR Pharmaceuticals

Drug Profile

Somatropin - JCR Pharmaceuticals

Alternative Names: Growject; JR-142; JR-401A; JR-401S; Somatropin-long-acting - JCR Pharmaceuticals

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator JCR Pharmaceuticals; Savient Pharmaceuticals
  • Developer JCR Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Preclinical Growth disorders

Most Recent Events

  • 06 Nov 2015 Preclinical trials in Growth disorders in Japan (unspecified route) (long-acting somatropin)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 16 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top